Showing results (151-160 of 207) with videos related to
Sort By:
Pageof 21
British Journal of Haematology|October 10, 2017
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patientsMichael Pfreundschuh, Niels Murawski, Samira Zeynalova, et al.The Lancet. Oncology|April 11, 2008
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) studyMichael Pfreundschuh, Anthony D Ho, Eva Cavallin-Stahl, et al.Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.Leukemia|June 30, 2018
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targetingLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.Blood|May 4, 2011
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker ConsortiumGilles Salles, Daphne de Jong, Wanling Xie, et al.Blood|October 27, 2007
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Martin Dreyling, Wolfram Klapper, et al.Blood|January 22, 2013
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphomaHeike Horn, Marita Ziepert, Claudia Becher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trialAndreas Engert, Jeremy Franklin, Hans Theodor Eich, et al.International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.Pageof 21